Taconic acquires TransCure bioServices

Taconic Biosciences, a prominent name in genetically engineered rodent models, has acquired France-based TransCure bioServices, a specialist in preclinical research services using humanized immune system (HIS) mouse models. While financial terms were not disclosed, the acquisition is strategically significant as it positions Taconic to offer a comprehensive global platform in translational research, particularly enhancing humanized model solutions for the biotech and pharmaceutical sectors.

Through this acquisition, Taconic aims to integrate its global production capacity and established genetic engineering expertise with TransCure’s advanced disease-specific translational pharmacology and high-end analytical capabilities such as flow cytometry, immune profiling, and imaging. This integration is expected to provide researchers with a more cohesive and efficient alternative to fragmented multi-vendor processes, with offerings that range from model generation and humanization to advanced therapeutic studies.

Taconic’s CEO, Mike Garrett, highlighted the potential of the acquisition to create a robust suite of preclinical solutions, covering a range of therapeutic areas including oncology, immunology, and infectious diseases. TransCure’s CEO, Sebastien Tabruyn, expressed optimism about the increased capabilities and enhanced value delivery to researchers worldwide as a result of joining forces with Taconic.

The consolidation reflects a broader trend of integration in the life sciences sector, where companies are increasingly seeking to unify fragmented workflows to improve efficiencies and outcomes in drug discovery and development. By leveraging a unified platform, Taconic aims to offer enhanced predictability and speed in drug development, benefiting from expanded geographic reach and an enriched inventory of proprietary models.

Going forward, Taconic and TransCure will maintain separate operational structures to ensure continuity for their employees and clients. The partnership is expected to accelerate the time to data generation and decision-making in drug development processes, focusing on mechanism-driven therapies. However, the deal's success will likely depend on the seamless integration of services and the ability to maintain high quality and innovation standards across both entities' offerings.